AI assistant
RHYTHM PHARMACEUTICALS, INC. — Director's Dealing 2025
Feb 11, 2025
30849_dirs_2025-02-11_dbc53a32-252f-4306-8b65-e8ec1ae66df4.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: RHYTHM PHARMACEUTICALS, INC. (RYTM)
CIK: 0001649904
Period of Report: 2025-02-09
Reporting Person: Shulman Joseph (Chief Technical Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2025-02-09 | Common Stock | M | 2656 | — | Acquired | 5313 | Direct |
| 2025-02-11 | Common Stock | M | 1562 | — | Acquired | 6875 | Direct |
| 2025-02-11 | Common Stock | S | 791 | $57.51 | Disposed | 6084 | Direct |
| 2025-02-11 | Common Stock | S | 3 | $57.54 | Disposed | 6.081 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2025-02-09 | Restricted Stock Units | $ | M | 2656 | Disposed | Common Stock (2656) | Direct | |
| 2025-02-11 | Restricted Stock Units | $ | M | 1562 | Disposed | Common Stock (1562) | Direct |
Footnotes
F1: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock.
F2: The sale reported in this Form 4 was effected pursuant to Rule 10b5-1 instruction adopted prior to February 27, 2023 solely with the intent to cover withholding taxes in connection with the vesting of certain previously reported restricted stock units.
F3: The restricted stock units vest or have vested as to 25% of the total shares on each of February 9, 2023, February 9, 2024, February 9, 2025 and February 9, 2026. The restricted stock units have no expiration date.
F4: The restricted stock units vest or have vested as to 25% of the total shares on each of February 11, 2022, February 11, 2023, February 11, 2024 and February 11, 2025. The restricted stock units have no expiration date.